Last reviewed · How we verify

CV0601 mRNA COVID-19 Vaccine

GlaxoSmithKline · Phase 2 active Biologic

CV0601 mRNA COVID-19 Vaccine is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 2 development for Prevention of COVID-19 disease caused by SARS-CoV-2 virus.

CV0601 mRNA COVID-19 Vaccine works by instructing cells to produce a piece of the SARS-CoV-2 virus, prompting an immune response.

CV0601 mRNA COVID-19 Vaccine works by instructing cells to produce a piece of the SARS-CoV-2 virus, prompting an immune response. Used for Prevention of COVID-19 disease caused by SARS-CoV-2 virus.

At a glance

Generic nameCV0601 mRNA COVID-19 Vaccine
SponsorGlaxoSmithKline
ModalityBiologic
Therapeutic areaImmunology
PhasePhase 2

Mechanism of action

This vaccine uses messenger RNA (mRNA) to encode the SARS-CoV-2 spike protein, which is then produced by cells and recognized by the immune system as foreign, triggering an immune response. This response helps to protect against future infections by providing immunity to the virus.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about CV0601 mRNA COVID-19 Vaccine

What is CV0601 mRNA COVID-19 Vaccine?

CV0601 mRNA COVID-19 Vaccine is a Biologic drug developed by GlaxoSmithKline, indicated for Prevention of COVID-19 disease caused by SARS-CoV-2 virus.

How does CV0601 mRNA COVID-19 Vaccine work?

CV0601 mRNA COVID-19 Vaccine works by instructing cells to produce a piece of the SARS-CoV-2 virus, prompting an immune response.

What is CV0601 mRNA COVID-19 Vaccine used for?

CV0601 mRNA COVID-19 Vaccine is indicated for Prevention of COVID-19 disease caused by SARS-CoV-2 virus.

Who makes CV0601 mRNA COVID-19 Vaccine?

CV0601 mRNA COVID-19 Vaccine is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What development phase is CV0601 mRNA COVID-19 Vaccine in?

CV0601 mRNA COVID-19 Vaccine is in Phase 2.

What are the side effects of CV0601 mRNA COVID-19 Vaccine?

Common side effects of CV0601 mRNA COVID-19 Vaccine include Pain, redness, swelling, or itching at the injection site, Fatigue, Headache, Muscle pain, Chills.

Related